# Scholar Rock

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scholar-rock

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.scholarrock.com
- Total disclosed funding: $103M
- Latest round: Series C (Dec 22, 2017)
- Investors on record: 8

## About

Scholar Rock, Inc. is a biopharmaceutical company focused on developing innovative therapies that selectively inhibit growth factors involved in serious diseases, aiming to improve patient outcomes through targeted treatment solutions.Founded in 2012 and headquartered in Cambridge, US, Scholar Rock, Inc. is dedicated to the discovery and development of biopharmaceutical therapies. The company has raised a total of USD 85.00 mn through various funding rounds, including a Private Placement/Follow on in October 2020 that secured USD 85.00 mn. Notably, the firm has executed 10 deals to date. The company was co-founded by Leonard Zon and Nagesh Mahanthappa, with Tony Kingsley serving as CEO.Scholar Rock specializes in developing innovative biopharmaceutical therapies that specifically target growth factors critical to a range of serious diseases. Their approach involves selective inhibition of protein growth factors prior to their activation, addressing the underlying causes of conditions including Spinal Muscular Atrophy (SMA) and certain fibrotic diseases. Their therapies are aimed at healthcare providers, hospitals, and specialty clinics in the US and select international markets, focusing on conditions inadequately treated by existing options.In 2022, Scholar Rock reported revenue of USD 33.19 mn. The firm has a negative EBITDA of USD 171.29 mn for 2023. The revenue is generated through partnerships and collaborations in the pharmaceutical sector, which typically involve milestone payments and royalties as therapies progress through clinical stages.Scholar Rock aims to expand its product offerings, with strategic plans to launch upcoming therapies designed to address critical medical needs in targeted markets. Their future growth strategy includes leveraging recent funding from the October 2020 round, which will support the advancement of their therapies through clinical trials and commercialization processes. The company is also focused on expanding its presence in international markets to reach a broader patient base suffering from conditions that lack effective treatments.

## Funding rounds

- Series C, Dec 22, 2017, $47M — ARCH Venture Partners, Polaris Partners, Invus [DUP], Fidelity Investments, Redmile Group, Kraft Group, EcoR1 Capital, Cormorant Asset Management
- Series B, Jan 4, 2016, $36M — ARCH Venture Partners, Polaris Partners, Fidelity Investments, Kraft Group, EcoR1 Capital, Cormorant Asset Management
- Series A, Sep 15, 2014, $20M — ARCH Venture Partners, Polaris Partners, Kraft Group, EcoR1 Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Kraft Group — Series A, Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A, Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Invus [DUP] — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C